Innovation Pharmaceuticals Inc (IPIX)

[JB3729]

According to the 10-Q for the period ending 9/30/14, Cellceutix has enough cash and $$$ available from the second Aspire financing ($7.09 + $9.60 million) to operate through 9/30/15 without touching the most recent shelf they filed.

We currently have an approximate $7.09 million cash balance in thebank but that is insufficient to complete the development and 
commercialization of any of ourproposed products. We expect to 
incur costs of approximately $16.8 million in the upcoming twelve months to operate our business in accordance with our business plans and budgets.

The Company is never under any obligation to sell shares to AspireCapital Fund. Aspire Capital Fund has no rights to require the 
Company to sell shares.

During the period from October 25, 2013 to September 30, 2014, theCompany had completed sales to Aspire totaling 5,900,000 
shares ofcommon stock generating
gross proceeds of approximately $10.40 million. As of September 30, 2014, a balance of $9.60 million remains and is available 
under the financing arrangement.

From October 1, 2014 to October 27, 2014, the Company has 
generated additional proceeds of approximately $1,914,000 under 
the Common Stock PurchaseAgreement with Aspire from the sale 
800,000 shares of its common stock.

Based on the last report, how much money was still available through the Aspire deal?